{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:35:28Z","timestamp":1774946128310,"version":"3.50.1"},"reference-count":67,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1080\/13543784.2020.1797677","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:51:22Z","timestamp":1595501482000},"page":"1025-1041","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Type I interferon antagonists in clinical development for lupus"],"prefix":"10.1080","volume":"29","author":[{"given":"Jacqueline L.","family":"Paredes","sequence":"first","affiliation":[{"name":"Colton Center for Autoimmunity,  New York University School of Medicine , New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Niewold","sequence":"additional","affiliation":[{"name":"Colton Center for Autoimmunity,  New York University School of Medicine , New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-017-0178-6"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0071"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.004"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.11.009"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00319"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2015.09.058"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064890"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1186\/ar3101"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.57"},{"key":"cit0012","author":"Ghodke-Puranik Y","year":"2019","journal-title":"Cytokine"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364408"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208140"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/art.23191"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/art.30187"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021553"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0337679100"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.31"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.02.011"},{"key":"cit0022","doi-asserted-by":"crossref","unstructured":"Greth W , Robbie GJ, Brohawn P, et al. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. 2017;9(1):57\u201370.","DOI":"10.2217\/imt-2016-0090"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew262"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0394-x"},{"key":"cit0025","doi-asserted-by":"crossref","unstructured":"Lauwerys BR , Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1\u2013kinoid. Arthritis Rheum. 2013;65(2):447\u2013456.","DOI":"10.1002\/art.37785"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216379"},{"key":"cit0027","doi-asserted-by":"crossref","unstructured":"Apostolopoulos D , \n                     Kandane-Rathnayake R , \n                     Louthrenoo W , et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol. 2020;2(1):e24\u2013e30.","DOI":"10.1016\/S2665-9913(19)30105-5"},{"key":"cit0028","unstructured":"Neovacs N   Announce the Results of its Phase IIB study for IFN\u03b1 KINOID in the treatment of Lupus which allows to proceed with the clinical development into Phase III. 2018."},{"key":"cit0029","doi-asserted-by":"crossref","unstructured":"McBride JM , Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666\u20133676.","DOI":"10.1002\/art.34632"},{"key":"cit0030","doi-asserted-by":"crossref","unstructured":"Maurer B , Bosanac I, Shia S,\u00a0et al. Structural basis of the broadly neutralizing anti-interferon-\u03b1 antibody rontalizumab. Protein Sci. 2015;24(9):1440\u20131450.","DOI":"10.1002\/pro.2729"},{"key":"cit0031","doi-asserted-by":"crossref","unstructured":"Kalunian KC , Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196\u2013202.","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"cit0032","doi-asserted-by":"crossref","unstructured":"Merrill JT , Wallace DJ, Petri M,\u00a0et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70(11):1905\u20131913.","DOI":"10.1136\/ard.2010.144485"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1002\/art.37824"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0085-2"},{"key":"cit0035","doi-asserted-by":"crossref","unstructured":"Zheng B , Yu XQ, Greth W,\u00a0et al. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol. 2016;81(5):918\u2013928.","DOI":"10.1111\/bcp.12864"},{"key":"cit0036","doi-asserted-by":"crossref","unstructured":"Khamashta M , Merrill JT, Werth VP,\u00a0et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909\u20131916.","DOI":"10.1136\/annrheumdis-2015-208562"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1583832"},{"key":"cit0038","doi-asserted-by":"crossref","unstructured":"Crow MK , \n                     R\u00f6nnblom L  . Report of the inaugural interferon research summit: interferon in inflammatory diseases. Lupus Sci Med. 2018;5(1):e000276.","DOI":"10.1136\/lupus-2018-000276"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.11.001"},{"key":"cit0040","doi-asserted-by":"crossref","unstructured":"Tcherepanova I , Curtis\u00a0M,\u00a0Sale\u00a0M,\u00a0et al. SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-\u03b1 monoclonal antibody in subjects with systemic lupus erythematosus. Annal Rheumat Dis. 2013;71(Suppl 3):536\u2013537.","DOI":"10.1136\/annrheumdis-2012-eular.3140"},{"key":"cit0041","unstructured":"Therapeutics A  , Argos therapeutics initiates dosing of patients in phase 1 clinical trial of monoclonal antibody-based therapy for treatment of systemic lupus erythematosus. 2010."},{"key":"cit0042","doi-asserted-by":"crossref","unstructured":"Farinha F , \n                     Isenberg DA  . Advances in IFN-alpha targeting-approaches for SLE treatment. Drugs Fut. 2015;40(9):129.","DOI":"10.1358\/dof.2015.40.9.2377844"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00229-3"},{"key":"cit0044","doi-asserted-by":"crossref","unstructured":"Riggs JM , Hanna RN, Rajan B,\u00a0et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261.","DOI":"10.1136\/lupus-2018-000261"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170969"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007810"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1583833"},{"key":"cit0048","doi-asserted-by":"crossref","unstructured":"Tummala R , Rouse T, Berglind A,\u00a0et al. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252.","DOI":"10.1136\/lupus-2017-000252"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000284"},{"key":"cit0051","volume-title":"PK\/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: a phase-II study in interferon type I high patients with active skin disease. in ARTHRITIS & RHEUMATOLOGY","author":"Bruce I","year":"2019"},{"key":"cit0052","doi-asserted-by":"crossref","unstructured":"Anderson E , \n                     Furie R  . Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. Immunotherapy. 2020;12(5):275\u2013286.","DOI":"10.2217\/imt-2020-0017"},{"key":"cit0053","doi-asserted-by":"crossref","unstructured":"Furie RA , \n                     Morand EF , \n                     Bruce IN , et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. N Engl J Med. 2019;1(4)e208\u2013e219.","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1112270"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.05.012"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1002\/art.30598"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1878-y"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/art.34483"},{"key":"cit0060","doi-asserted-by":"crossref","unstructured":"Thanarajasingam U , \n                     Muppirala AN , \n                     Jensen MA , et al. Type I interferon predicts an alternate immune system phenotype in systemic lupus erythematosus. ACR Open Rheumatol. 2019;1(8):499\u2013506.","DOI":"10.1002\/acr2.11073"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1002\/art.20798"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161451"},{"key":"cit0063","doi-asserted-by":"crossref","unstructured":"Salmon JE , \n                     Niewold TB  . A successful trial for lupus \u2014 how good is good enough? N Engl J Med.\u00a02019;382(3):287\u2013288.","DOI":"10.1056\/NEJMe1915490"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519884249"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.4061\/2009\/374312"},{"key":"cit0066","author":"Furie R","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"cit0067","author":"Chatham W","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1797677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T14:03:28Z","timestamp":1602425008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1797677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1080\/13543784.2020.1797677"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1797677","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}